MOTS‑c (mitochondrial open reading frame of the 12S rRNA type‑C) is a tiny 16‑amino‑acid peptide naturally produced by our mitochondrial DNA. Dr. Jason Schuster explains that supplementing MOTS‑c can help restore the energy‑producing capacity of cells and address chronic fatigue.
Mitochondrial‑Derived Peptide
MOTS‑c is encoded by the 12S RNA segment of mitochondrial DNA and consists of only 16 amino acids, making it much smaller than peptides like thymosin beta‑4 (43 aa) or thymosin alpha‑1 (30+ aa). Because it originates from mitochondria, its primary site of action is the organelle that produces the body’s ATP.
- 16 amino acids long
- Encoded by mitochondrial 12S rRNA
- Naturally produced during exercise
How MOTS‑c Talks to the Cell
According to Dr. Schuster, MOTS‑c enhances communication between mitochondrial DNA and nuclear DNA, boosting transcription of genes that govern muscle metabolism, insulin response, and energy production. It also raises intracellular NAD⁺ levels, a co‑factor required for ATP synthesis, and activates the NRF2 anti‑inflammatory pathway.
- Improves mitochondrial‑nuclear signaling
- Elevates NAD⁺ → more ATP
- Activates NRF2 anti‑inflammatory pathway
- Enhances insulin sensitivity and glucose flux
Key Health Impacts
Dr. Schuster cites several therapeutic areas where MOTS‑c shows promise: it can increase energy and aid weight loss, improve insulin resistance, reduce pro‑inflammatory cytokines (TNF‑α, IL‑1, IL‑6), raise anti‑inflammatory cytokines (IL‑10), and protect against cardiovascular injury. He also notes potential usefulness for chronic fatigue and recovery from COVID‑related vaccine side effects.
- Higher energy and reduced chronic fatigue
- Improved insulin resistance and glucose handling
- Anti‑inflammatory effects via cytokine modulation
- Support for cardiovascular health
- Possible aid in COVID‑vaccine injury recovery
Practical Use
The protocol most often referenced by Dr. Schuster comes from Dr. Edin Lee: 10 mg of MOTS‑c administered subcutaneously once weekly, often on a rotational schedule (e.g., one‑to‑two months on, one‑to‑two months off). Some clinicians use it only once or twice a year. Circulating MOTS‑c levels are about 20 % higher in young adults than in older adults, suggesting supplementation may be especially beneficial with age. Reported side effects are minimal, and the peptide is described as “super safe.”
- 10 mg subcutaneous weekly (rotational schedule common)
- Occasional use: once or twice per year
- Older adults have ~20% lower baseline levels
- Very low adverse‑event profile
“By delivering the proteins directly, you bypass the energy the mitochondria would need to make them, and the proteins then positively influence DNA expression.”— Dr. Jason Schuster
Dr. Schuster's short takes on this topic — tap to play.
Go deeper than the summary
Dr. Schuster's accredited courses on supplementation, epigenetics, and peptide therapy — the full research, dosing, and video breakdowns.